Why Is Abbott Laboratories (ABT) Stock Up +12.22% Today?
Key Takeaways
- Abbott Laboratories shares surged 12.22% to $100.18 in midday trading Thursday, rebounding sharply from the prior session's close of $89.27.
- Second-quarter 2026 earnings beat expectations, with adjusted diluted EPS of $1.31 topping the consensus estimate of $1.28 and net sales of $12.59 billion rising 13.0% year over year.
- Full-year 2026 adjusted EPS guidance was raised to a range of $5.45 to $5.60, up from the prior $5.38 to $5.58, signaling management confidence in the back half of the year.
- Medical Devices and the newly acquired Cancer Diagnostics business drove outperformance, with comparable sales growth of 8.4% in Devices and mid-teens growth in Cologuard within Cancer Diagnostics.
- The rally marks a sharp reversal after weeks of pressure tied to litigation concerns, Nutrition segment weakness, and broader healthcare sector rotation.
- Traders are now watching for sustained volume follow-through, analyst revisions, and the upcoming Q3 2026 guidance trajectory.
Opening Summary
ABT, the global healthcare giant behind brands such as FreeStyle Libre, Similac, Ensure, and the recently acquired Cologuard cancer screening platform, staged a powerful rally on Thursday. Shares of Abbott Laboratories jumped 12.22% to $100.18 as of 1:43 p.m. ET, rocketing from Wednesday's close of $89.27. The catalyst was unambiguous: a second-quarter earnings report released before the opening bell that delivered an across-the-board beat, headlined by adjusted earnings per share of $1.31 versus the Street's $1.28 forecast, and an upward revision to the company's full-year profit outlook. The move marks the stock's strongest single-session advance in years and reverses a multi-week slide that had pushed shares to levels not seen since early 2024.
Earnings Beat and Raised Guidance Fuel the Rally
Abbott reported Q2 2026 net sales of $12.593 billion, representing 13.0% reported growth and 4.8% comparable sales growth year over year. Adjusted diluted EPS came in at $1.31, exceeding the analyst consensus of $1.28 and the company's own guidance range of $1.25 to $1.31. GAAP diluted EPS was $0.53, weighed down by $1.362 billion in specified after-tax charges, including $658 million of intangible amortization and costs tied to the Exact Sciences acquisition, legal reserves, and tax adjustments.
More importantly for forward-looking investors, management raised its full-year 2026 adjusted EPS guidance to $5.45–$5.60, up from the prior range of $5.38–$5.58. The company also initiated third-quarter adjusted EPS guidance of $1.38–$1.46, comfortably above the $1.28 the Street had been modeling for Q2. Full-year comparable sales growth guidance was reaffirmed at 6.5% to 7.5%. The combination of a clean beat and a guidance raise—after a punishing stretch in which the stock had fallen roughly 31% from its 52-week high—triggered an aggressive wave of buying.
Medical Devices and Cancer Diagnostics Lead Segment Strength
The Medical Devices segment, Abbott's largest and highest-multiple business, delivered comparable sales growth of 8.4% in the quarter. Electrophysiology posted low-teens growth, driven by the Volt and TactiFlex Duo pulsed field ablation catheters. Rhythm Management extended its streak of double-digit gains, supported by the Aveir leadless pacemaker, while Heart Failure and Diabetes Care also contributed solid performances. FreeStyle Libre continuous glucose monitor sales returned to double-digit growth in the quarter, a key milestone after a period of deceleration that had weighed on sentiment.
Diagnostics reported comparable growth of 2.9%, but the headline masked a standout performance in the newly formed Cancer Diagnostics division. Following the March 23, 2026 acquisition of Exact Sciences, Cologuard posted mid-teens growth in the U.S. and high-teens growth internationally. The American Cancer Society's updated colorectal cancer screening guidelines, which reaffirmed Cologuard and Cologuard Plus as preferred non-invasive options, provided an additional tailwind. Core Laboratory Diagnostics also grew, supported by steady demand across the U.S., Europe, and Latin America.
Nutrition Stabilizes, Easing a Key Investor Concern
The Nutrition segment, which had been a persistent drag on Abbott's stock amid pricing resets, litigation overhang related to necrotizing enterocolitis claims, and manufacturing facility scrutiny, showed signs of stabilization. While worldwide Nutrition sales declined 3.6% on a comparable basis, the segment posted a sequential revenue increase of $127 million compared to Q1 2026. Management's strategic pricing actions implemented in late 2025 are beginning to take hold, and the launch of several new products is expected to support improved volume trends through the remainder of the year. The absence of negative surprises in this segment removed a key overhang that had kept institutional investors on the sidelines.
Market Context and Trading Activity
The magnitude of Thursday's move was amplified by the stock's deeply oversold condition entering the session. ABT had declined in seven of the prior nine trading days, falling from above $94 to $89.27, and was trading at a forward price-to-earnings multiple of roughly 16 times—well below its five-year median of approximately 23 times. The earnings beat and guidance raise served as a powerful catalyst for a mean-reversion trade, with volume surging well above the daily average as both institutional and algorithmic participants rushed to reprice the stock.
The rally was not driven by broader market forces. The healthcare sector had been underperforming in recent sessions, and Abbott's move was decisively company-specific. The stock sliced through its 50-day moving average, which had acted as resistance during the recent downturn, and approached levels not seen since late June. The speed and scale of the advance suggest short-covering may have contributed, as bearish positioning had built up during the stock's prolonged slide.
Trending AI Robots
For traders seeking to navigate volatile market environments with a data-driven approach, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that cover thousands of tickers across a wide range of strategies, timeframes, and performance metrics. The Trending AI Robots section highlights only the strongest-performing bots under current market conditions, allowing users to identify strategies that are adapting successfully to real-time market dynamics. Whether focused on swing trading, trend following, or pattern recognition, these bots provide a systematic complement to traditional analysis. Explore the Trending AI Robots page to see which strategies are resonating in today's market.
What Comes Next for ABT
With the Q2 report now in the rearview mirror, attention shifts to Abbott's ability to sustain the momentum through the second half of 2026. The raised full-year guidance implies accelerating earnings growth in Q3 and Q4, and the company's pipeline—including the TECTONIC coronary IVL trial, the Amulet 360 LAA device under FDA review, and the recently CE Marked Libre Duo glucose-ketone sensor—provides a runway for continued product-driven expansion. The Exact Sciences integration remains a critical variable; investors will monitor whether Cancer Diagnostics can maintain its mid-teens growth trajectory and whether acquisition-related dilution narrows faster than expected.
Risks remain. The Nutrition segment's legal challenges, particularly the approaching bellwether trials related to necrotizing enterocolitis claims, could resurface as a sentiment headwind. Competitive dynamics in the continuous glucose monitoring market bear watching, as rival product launches and evolving reimbursement landscapes may pressure FreeStyle Libre's market share. Macroeconomic factors, including foreign exchange fluctuations and healthcare utilization patterns, will also influence results. For now, however, the Q2 report has given the bulls a decisive edge, and the burden of proof has shifted back to the skeptics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ABT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ABT turned positive on July 16, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 16, 2026. You may want to consider a long position or call options on ABT as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
ABT moved above its 50-day moving average on July 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 254 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ABT broke above its upper Bollinger Band on July 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.766) is normal, around the industry mean (11.053). P/E Ratio (36.010) is within average values for comparable stocks, (73.178). Projected Growth (PEG Ratio) (2.240) is also within normal values, averaging (3.988). Dividend Yield (0.022) settles around the average of (0.016) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (31.009).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement